25 XP   0   0   10

NervGen Pharma Corp
Buy, Hold or Sell?

Let's analyse Nervgen together

PenkeI guess you are interested in NervGen Pharma Corp. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of NervGen Pharma Corp. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about NervGen Pharma Corp

I send you an email if I find something interesting about NervGen Pharma Corp.

Quick analysis of Nervgen (30 sec.)










What can you expect buying and holding a share of Nervgen? (30 sec.)

How much money do you get?

How much money do you get?
C$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
C$0.09
Expected worth in 1 year
C$-0.14
How sure are you?
40.9%

+ What do you gain per year?

Total Gains per Share
C$-0.22
Return On Investment
-10.2%

For what price can you sell your share?

Current Price per Share
C$2.20
Expected price per share
C$2.07 - C$3.7
How sure are you?
50%

1. Valuation of Nervgen (5 min.)




Live pricePrice per Share (EOD)

C$2.20

Intrinsic Value Per Share

C$-1.87 - C$-2.17

Total Value Per Share

C$-1.79 - C$-2.08

2. Growth of Nervgen (5 min.)




Is Nervgen growing?

Current yearPrevious yearGrowGrow %
How rich?$3.7m$10.6m-$4m-60.8%

How much money is Nervgen making?

Current yearPrevious yearGrowGrow %
Making money-$3.6m-$3.4m-$144.4k-4.0%
Net Profit Margin0.0%0.0%--

How much money comes from the company's main activities?

3. Financial Health of Nervgen (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#787 / 1031

Most Revenue
#758 / 1031

Most Profit
#409 / 1031

Most Efficient
#207 / 1031

What can you expect buying and holding a share of Nervgen? (5 min.)

Welcome investor! Nervgen's management wants to use your money to grow the business. In return you get a share of Nervgen.

What can you expect buying and holding a share of Nervgen?

First you should know what it really means to hold a share of Nervgen. And how you can make/lose money.

Speculation

The Price per Share of Nervgen is C$2.2. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Nervgen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Nervgen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is C$0.09. Based on the TTM, the Book Value Change Per Share is C$-0.06 per quarter. Based on the YOY, the Book Value Change Per Share is C$0.04 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is C$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Nervgen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 C$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per ShareC$% of Price per Share
Usd Eps-0.05-2.4%-0.06-2.8%-0.06-2.7%-0.04-1.9%-0.04-1.8%
Usd Book Value Change Per Share-0.03-1.4%-0.04-1.9%0.031.4%0.000.1%0.000.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.03-1.4%-0.04-1.9%0.031.4%0.000.1%0.000.1%
Usd Price Per Share1.41-1.25-1.53-1.25-1.13-
Price to Earnings Ratio-6.64--5.22--6.89--7.80--7.09-
Price-to-Total Gains Ratio-46.59--33.78--8.72--15.50--15.50-
Price to Book Ratio22.37-13.06-8.93-12.82-11.66-
Price-to-Total Gains Ratio-46.59--33.78--8.72--15.50--15.50-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.61986
Number of shares617
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.040.00
Usd Total Gains Per Share-0.040.00
Gains per Quarter (617 shares)-25.400.71
Gains per Year (617 shares)-101.582.83
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-102-11203-7
20-203-21406-4
30-305-31608-1
40-406-4180112
50-508-5200145
60-609-6220178
70-711-72402011
80-813-82602314
90-914-92802517
100-1016-103002820

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%0.022.00.00.0%0.022.00.00.0%
Book Value Change Per Share0.04.00.00.0%4.08.00.033.3%7.013.00.035.0%9.013.00.040.9%9.013.00.040.9%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.022.00.0%0.00.022.00.0%
Total Gains per Share0.04.00.00.0%4.08.00.033.3%7.013.00.035.0%9.013.00.040.9%9.013.00.040.9%

Fundamentals of Nervgen

About NervGen Pharma Corp

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Fundamental data was last updated by Penke on 2024-03-11 10:13:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of NervGen Pharma Corp.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Nervgen earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Nervgen to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of NervGen Pharma Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--159.2%+159.2%
TTM--202.3%+202.3%
YOY--263.0%+263.0%
5Y--452.4%+452.4%
10Y--589.0%+589.0%
1.1.2. Return on Assets

Shows how efficient Nervgen is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Nervgen to the Biotechnology industry mean.
  • -26.3% Return on Assets means that Nervgen generated $-0.26 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of NervGen Pharma Corp:

  • The MRQ is -26.3%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -25.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-26.3%TTM-25.8%-0.5%
TTM-25.8%YOY-29.9%+4.1%
TTM-25.8%5Y-32.2%+6.4%
5Y-32.2%10Y-30.1%-2.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-26.3%-12.5%-13.8%
TTM-25.8%-12.2%-13.6%
YOY-29.9%-11.2%-18.7%
5Y-32.2%-13.3%-18.9%
10Y-30.1%-14.6%-15.5%
1.1.3. Return on Equity

Shows how efficient Nervgen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Nervgen to the Biotechnology industry mean.
  • -84.2% Return on Equity means Nervgen generated $-0.84 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of NervGen Pharma Corp:

  • The MRQ is -84.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -59.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-84.2%TTM-59.8%-24.5%
TTM-59.8%YOY-36.6%-23.1%
TTM-59.8%5Y-43.0%-16.8%
5Y-43.0%10Y-40.1%-2.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-84.2%-16.0%-68.2%
TTM-59.8%-15.8%-44.0%
YOY-36.6%-13.9%-22.7%
5Y-43.0%-18.2%-24.8%
10Y-40.1%-19.1%-21.0%

1.2. Operating Efficiency of NervGen Pharma Corp.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Nervgen is operating .

  • Measures how much profit Nervgen makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Nervgen to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of NervGen Pharma Corp:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y-0.0%
5Y-10Y-0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--299.5%+299.5%
TTM--208.5%+208.5%
YOY--280.2%+280.2%
5Y--459.9%+459.9%
10Y--596.9%+596.9%
1.2.2. Operating Ratio

Measures how efficient Nervgen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of NervGen Pharma Corp:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.000
TTM-YOY-0.000
TTM-5Y-0.000
5Y-10Y-0.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.817-2.817
TTM-3.181-3.181
YOY-3.609-3.609
5Y-5.554-5.554
10Y-7.396-7.396

1.3. Liquidity of NervGen Pharma Corp.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Nervgen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.40 means the company has $1.40 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of NervGen Pharma Corp:

  • The MRQ is 1.402. The company is just able to pay all its short-term debts.
  • The TTM is 1.858. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.402TTM1.858-0.455
TTM1.858YOY8.787-6.930
TTM1.8585Y9.420-7.562
5Y9.42010Y9.129+0.291
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4023.987-2.585
TTM1.8584.440-2.582
YOY8.7875.569+3.218
5Y9.4206.158+3.262
10Y9.1296.492+2.637
1.3.2. Quick Ratio

Measures if Nervgen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Nervgen to the Biotechnology industry mean.
  • A Quick Ratio of 0.00 means the company can pay off $0.00 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of NervGen Pharma Corp:

  • The MRQ is 0.002. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.005. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.002TTM0.005-0.003
TTM0.005YOY0.040-0.035
TTM0.0055Y0.054-0.050
5Y0.05410Y0.051+0.003
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0023.653-3.651
TTM0.0054.158-4.153
YOY0.0405.515-5.475
5Y0.0546.012-5.958
10Y0.0516.206-6.155

1.4. Solvency of NervGen Pharma Corp.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Nervgen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Nervgen to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.69 means that Nervgen assets are financed with 68.8% credit (debt) and the remaining percentage (100% - 68.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of NervGen Pharma Corp:

  • The MRQ is 0.688. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.543. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.688TTM0.543+0.145
TTM0.543YOY0.186+0.358
TTM0.5435Y0.210+0.334
5Y0.21010Y0.2100.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6880.336+0.352
TTM0.5430.330+0.213
YOY0.1860.267-0.081
5Y0.2100.367-0.157
10Y0.2100.378-0.168
1.4.2. Debt to Equity Ratio

Measures if Nervgen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Nervgen to the Biotechnology industry mean.
  • A Debt to Equity ratio of 220.3% means that company has $2.20 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of NervGen Pharma Corp:

  • The MRQ is 2.203. The company is just not able to pay all its debts with equity.
  • The TTM is 1.303. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ2.203TTM1.303+0.900
TTM1.303YOY0.259+1.045
TTM1.3035Y0.386+0.918
5Y0.38610Y0.377+0.009
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2030.376+1.827
TTM1.3030.398+0.905
YOY0.2590.334-0.075
5Y0.3860.431-0.045
10Y0.3770.476-0.099

2. Market Valuation of NervGen Pharma Corp

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Nervgen generates.

  • Above 15 is considered overpriced but always compare Nervgen to the Biotechnology industry mean.
  • A PE ratio of -6.64 means the investor is paying $-6.64 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of NervGen Pharma Corp:

  • The EOD is -7.607. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.639. Based on the earnings, the company is expensive. -2
  • The TTM is -5.223. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.607MRQ-6.639-0.968
MRQ-6.639TTM-5.223-1.416
TTM-5.223YOY-6.889+1.666
TTM-5.2235Y-7.797+2.574
5Y-7.79710Y-7.088-0.709
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.607-2.697-4.910
MRQ-6.639-2.422-4.217
TTM-5.223-2.709-2.514
YOY-6.889-4.116-2.773
5Y-7.797-6.257-1.540
10Y-7.088-6.478-0.610
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of NervGen Pharma Corp:

  • The EOD is -20.875. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -18.218. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -10.055. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-20.875MRQ-18.218-2.657
MRQ-18.218TTM-10.055-8.163
TTM-10.055YOY-8.507-1.548
TTM-10.0555Y-11.915+1.860
5Y-11.91510Y-10.832-1.083
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-20.875-3.344-17.531
MRQ-18.218-2.939-15.279
TTM-10.055-3.486-6.569
YOY-8.507-5.592-2.915
5Y-11.915-8.464-3.451
10Y-10.832-8.872-1.960
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Nervgen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 22.37 means the investor is paying $22.37 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of NervGen Pharma Corp:

  • The EOD is 25.633. Based on the equity, the company is expensive. -2
  • The MRQ is 22.371. Based on the equity, the company is expensive. -2
  • The TTM is 13.058. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD25.633MRQ22.371+3.262
MRQ22.371TTM13.058+9.313
TTM13.058YOY8.927+4.131
TTM13.0585Y12.823+0.235
5Y12.82310Y11.657+1.166
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD25.6332.198+23.435
MRQ22.3712.042+20.329
TTM13.0582.121+10.937
YOY8.9272.907+6.020
5Y12.8233.682+9.141
10Y11.6574.114+7.543
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of NervGen Pharma Corp compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.041-0.056+36%0.043-197%0.002-2746%0.004-1156%
Book Value Per Share--0.0860.151-43%0.243-65%0.146-41%0.136-37%
Current Ratio--1.4021.858-25%8.787-84%9.420-85%9.129-85%
Debt To Asset Ratio--0.6880.543+27%0.186+270%0.210+228%0.210+228%
Debt To Equity Ratio--2.2031.303+69%0.259+752%0.386+471%0.377+485%
Dividend Per Share----0%-0%-0%-0%
Eps---0.072-0.083+15%-0.080+10%-0.058-20%-0.053-26%
Free Cash Flow Per Share---0.026-0.056+114%-0.066+149%-0.042+58%-0.038+46%
Free Cash Flow To Equity Per Share---0.025-0.054+113%0.078-132%0.017-248%0.019-231%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---2.169--------
Intrinsic Value_10Y_min---1.875--------
Intrinsic Value_1Y_max---0.206--------
Intrinsic Value_1Y_min---0.203--------
Intrinsic Value_3Y_max---0.628--------
Intrinsic Value_3Y_min---0.600--------
Intrinsic Value_5Y_max---1.060--------
Intrinsic Value_5Y_min---0.983--------
Market Cap130914080.000+13%114252288.000101160880.000+13%123624546.000-8%100625322.400+14%91477565.818+25%
Net Profit Margin----0%-0%-0%-0%
Operating Margin----0%-0%-0%-0%
Operating Ratio----0%-0%-0%-0%
Pb Ratio25.633+13%22.37113.058+71%8.927+151%12.823+74%11.657+92%
Pe Ratio-7.607-15%-6.639-5.223-21%-6.889+4%-7.797+17%-7.088+7%
Price Per Share2.200+13%1.9201.700+13%2.078-8%1.691+14%1.537+25%
Price To Free Cash Flow Ratio-20.875-15%-18.218-10.055-45%-8.507-53%-11.915-35%-10.832-41%
Price To Total Gains Ratio-53.387-15%-46.592-33.783-27%-8.716-81%-15.500-67%-15.500-67%
Quick Ratio--0.0020.005-55%0.040-95%0.054-96%0.051-96%
Return On Assets---0.263-0.258-2%-0.299+14%-0.322+22%-0.301+14%
Return On Equity---0.842-0.598-29%-0.366-57%-0.430-49%-0.401-52%
Total Gains Per Share---0.041-0.056+36%0.043-197%0.002-2746%0.004-1156%
Usd Book Value--3760424.7336627984.291-43%10654972.266-65%6401664.705-41%5957577.435-37%
Usd Book Value Change Per Share---0.030-0.041+36%0.031-197%0.001-2746%0.003-1156%
Usd Book Value Per Share--0.0630.111-43%0.179-65%0.108-41%0.100-37%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.053-0.061+15%-0.059+10%-0.043-20%-0.039-26%
Usd Free Cash Flow---1154377.030-2467424.318+114%-2873049.963+149%-1824901.032+58%-1680111.061+46%
Usd Free Cash Flow Per Share---0.019-0.041+114%-0.048+149%-0.031+58%-0.028+46%
Usd Free Cash Flow To Equity Per Share---0.019-0.039+113%0.057-132%0.012-248%0.014-231%
Usd Market Cap96392037.104+13%84123959.65474484755.944+13%91024753.220-8%74090424.883+14%67354931.712+25%
Usd Price Per Share1.620+13%1.4141.252+13%1.530-8%1.245+14%1.132+25%
Usd Profit---3167966.829-3628835.590+15%-3484345.367+10%-2538110.038-20%-2326780.659-27%
Usd Revenue----0%-0%-0%-0%
Usd Total Gains Per Share---0.030-0.041+36%0.031-197%0.001-2746%0.003-1156%
 EOD+5 -3MRQTTM+17 -12YOY+9 -205Y+8 -2110Y+8 -21

3.2. Fundamental Score

Let's check the fundamental score of NervGen Pharma Corp based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.607
Price to Book Ratio (EOD)Between0-125.633
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.002
Current Ratio (MRQ)Greater than11.402
Debt to Asset Ratio (MRQ)Less than10.688
Debt to Equity Ratio (MRQ)Less than12.203
Return on Equity (MRQ)Greater than0.15-0.842
Return on Assets (MRQ)Greater than0.05-0.263
Total2/10 (20.0%)

3.3. Technical Score

Let's check the technical score of NervGen Pharma Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.822
Ma 20Greater thanMa 502.715
Ma 50Greater thanMa 1002.970
Ma 100Greater thanMa 2002.506
OpenGreater thanClose2.190
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-09-30. Currency in CAD. All numbers in thousands.

Summary
Total Assets16,360
Total Liabilities11,253
Total Stockholder Equity5,107
 As reported
Total Liabilities 11,253
Total Stockholder Equity+ 5,107
Total Assets = 16,360

Assets

Total Assets16,360
Total Current Assets15,601
Long-term Assets759
Total Current Assets
Cash And Cash Equivalents 14,786
Net Receivables 23
Total Current Assets  (as reported)15,601
Total Current Assets  (calculated)14,809
+/- 792
Long-term Assets
Property Plant Equipment 224
Intangible Assets 535
Long-term Assets  (as reported)759
Long-term Assets  (calculated)759
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities11,124
Long-term Liabilities129
Total Stockholder Equity5,107
Total Current Liabilities
Accounts payable 632
Other Current Liabilities 8,052
Total Current Liabilities  (as reported)11,124
Total Current Liabilities  (calculated)8,684
+/- 2,439
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt219
Long-term Liabilities  (as reported)129
Long-term Liabilities  (calculated)219
+/- 90
Total Stockholder Equity
Total Stockholder Equity (as reported)5,107
Total Stockholder Equity (calculated)0
+/- 5,107
Other
Capital Stock58,760
Common Stock Shares Outstanding 59,506
Net Invested Capital 5,107
Net Working Capital 4,477
Property Plant and Equipment Gross 224



Balance Sheet

Currency in CAD. All numbers in thousands.

 Trend2023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-30
> Total Assets 
1,233
3,725
3,097
9,757
8,946
7,060
6,765
5,427
6,129
10,249
6,675
6,308
8,694
9,378
17,896
13,895
12,984
28,883
23,875
19,099
17,415
16,360
16,36017,41519,09923,87528,88312,98413,89517,8969,3788,6946,3086,67510,2496,1295,4276,7657,0608,9469,7573,0973,7251,233
   > Total Current Assets 
748
3,168
2,550
9,219
8,417
6,541
6,256
4,923
5,635
9,766
6,202
5,845
8,199
8,891
17,420
13,426
12,193
28,121
23,149
18,410
16,758
15,601
15,60116,75818,41023,14928,12112,19313,42617,4208,8918,1995,8456,2029,7665,6354,9236,2566,5418,4179,2192,5503,168748
       Cash And Cash Equivalents 
745
3,122
2,474
9,099
8,270
6,273
4,106
2,512
3,456
7,656
5,599
4,987
7,360
8,249
16,929
12,828
11,650
27,700
22,452
18,021
16,083
14,786
14,78616,08318,02122,45227,70011,65012,82816,9298,2497,3604,9875,5997,6563,4562,5124,1066,2738,2709,0992,4743,122745
       Net Receivables 
2
12
26
54
61
100
123
7
7
6
63
33
58
42
64
70
97
27
27
90
40
23
234090272797706442583363677123100615426122
       Other Current Assets 
0
0
0
0
14
80
1,984
2,362
2,119
2,064
492
730
706
550
363
463
404
332
590
0
495
0
049505903324044633635507067304922,0642,1192,3621,98480140000
   > Long-term Assets 
0
0
0
538
529
519
510
503
493
483
473
463
495
487
476
470
790
761
727
689
657
759
759657689727761790470476487495463473483493503510519529538000
       Property Plant Equipment 
0
0
0
0
0
0
0
3
3
2
2
2
1
3
3
7
338
320
295
268
247
224
2242472682953203387331222330000000
       Intangible Assets 
485
556
548
538
529
519
510
500
490
481
471
462
494
484
473
463
452
442
431
421
411
535
535411421431442452463473484494462471481490500510519529538548556485
> Total Liabilities 
367
471
583
474
327
574
924
728
547
324
755
1,159
1,011
1,085
1,078
1,119
3,107
10,469
10,414
9,220
9,856
11,253
11,2539,8569,22010,41410,4693,1071,1191,0781,0851,0111,159755324547728924574327474583471367
   > Total Current Liabilities 
237
341
449
474
327
574
924
728
547
324
755
1,159
1,011
1,085
1,078
1,119
2,866
10,250
10,217
9,045
9,704
11,124
11,1249,7049,04510,21710,2502,8661,1191,0781,0851,0111,159755324547728924574327474449341237
       Accounts payable 
225
309
257
422
225
418
502
518
182
45
172
756
626
617
353
824
1,697
1,050
2,002
316
887
632
6328873162,0021,0501,69782435361762675617245182518502418225422257309225
       Other Current Liabilities 
0
0
134
280
15
14
0
0
0
0
0
238
0
278
274
134
0
8,070
6,732
6,878
6,823
8,052
8,0526,8236,8786,7328,0700134274278023800000141528013400
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
241
219
197
175
152
129
1291521751972192410000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
325
304
283
262
241
219
2192412622833043250000000000000000
> Total Stockholder Equity
866
3,254
2,514
9,283
8,619
6,487
5,842
4,699
5,581
9,926
5,920
5,150
7,683
8,293
16,818
12,776
9,877
18,413
13,461
9,879
7,559
5,107
5,1077,5599,87913,46118,4139,87712,77616,8188,2937,6835,1505,9209,9265,5814,6995,8426,4878,6199,2832,5143,254866
   Common Stock
953
3,847
3,847
12,651
13,331
13,331
15,294
15,441
17,796
22,869
22,947
24,011
27,940
31,224
42,403
42,552
45,256
56,784
57,412
0
58,594
0
058,594057,41256,78445,25642,55242,40331,22427,94024,01122,94722,86917,79615,44115,29413,33113,33112,6513,8473,847953
   Retained Earnings -69,545-65,242-60,480-55,771-49,831-46,335-40,016-35,049-30,902-27,302-24,569-22,322-17,750-15,617-12,995-11,136-8,248-5,917-4,392-1,370-602-87
   Capital Surplus 0000000000000000000000
   Treasury Stock0000000000000000000000
   Other Stockholders Equity 
0
0
38
1,024
1,205
1,404
1,684
2,253
3,402
4,807
5,295
5,708
7,045
7,971
9,464
10,240
10,955
11,460
11,820
0
14,208
0
014,208011,82011,46010,95510,2409,4647,9717,0455,7085,2954,8073,4022,2531,6841,4041,2051,0243800



Balance Sheet

Currency in CAD. All numbers in thousands.




Cash Flow

Currency in CAD. All numbers in thousands.




Income Statement

Currency in CAD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue0
Cost of Revenue--
Gross Profit-0
 
Operating Income (+$)
Gross Profit-
Operating Expense-19,686
Operating Income-19,686-19,686
 
Operating Expense (+$)
Research Development10,458
Selling General Administrative9,129
Selling And Marketing Expenses-
Operating Expense19,68619,588
 
Net Interest Income (+$)
Interest Income514
Interest Expense-0
Other Finance Cost-0
Net Interest Income514
 
Pretax Income (+$)
Operating Income-19,686
Net Interest Income514
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-19,714-19,145
EBIT - interestExpense = 0
-19,714
-19,714
Interest Expense0
Earnings Before Interest and Taxes (EBIT)--19,714
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-19,714
Tax Provision--
Net Income From Continuing Ops-19,714-19,714
Net Income-19,714
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-541-514
 

Technical Analysis of Nervgen
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Nervgen. The general trend of Nervgen is BULLISH with 14.3% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Nervgen's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (14.3%) Bearish trend (-14.3%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of NervGen Pharma Corp.

The long score for the Support & Resistance is 1/1.
The longshort score for the Support & Resistance is 1/(-1 +1).

  • Around support: The price is currently trading around a support level. This can be considered as a potential entry level. +1

The bullish price targets are: 2.5 < 2.82 < 3.7.

The bearish price targets are: 2.16 > 2.15 > 2.07.

Tweet this
NervGen Pharma Corp Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of NervGen Pharma Corp. The current mas is .

The long score for the Moving Averages is 8/14.
The longshort score for the Moving Averages is 2/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 > MA 200: The MA 20 is higher than the MA 200. +1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
  • MA 100 trending up: The MA 100 is trending up. +1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close > MA 200: The price is above the MA 200. +1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

NervGen Pharma Corp Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of NervGen Pharma Corp. The current macd is -0.25695679.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Nervgen price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Nervgen. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Nervgen price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
NervGen Pharma Corp Daily Moving Average Convergence/Divergence (MACD) ChartNervGen Pharma Corp Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of NervGen Pharma Corp. The current adx is 30.07.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Nervgen shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
NervGen Pharma Corp Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of NervGen Pharma Corp. The current sar is 2.399872.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
NervGen Pharma Corp Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of NervGen Pharma Corp. The current rsi is 31.82. The current phase is Correction in bull market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Correction in bull market: Moderate price decline, potential pause in the uptrend. Reassess the market, wait for signs of stabilization.
  • Trending up: The RSI is trending up. +1
NervGen Pharma Corp Daily Relative Strength Index (RSI) ChartNervGen Pharma Corp Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of NervGen Pharma Corp. The current phase is Oversold in bull market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 0/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Nervgen price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
NervGen Pharma Corp Daily Stochastic Oscillator ChartNervGen Pharma Corp Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of NervGen Pharma Corp. The current cci is -94.18825941.

NervGen Pharma Corp Daily Commodity Channel Index (CCI) ChartNervGen Pharma Corp Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of NervGen Pharma Corp. The current cmo is -43.6830853.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
NervGen Pharma Corp Daily Chande Momentum Oscillator (CMO) ChartNervGen Pharma Corp Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of NervGen Pharma Corp. The current willr is -80.95238095.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
NervGen Pharma Corp Daily Williams %R ChartNervGen Pharma Corp Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of NervGen Pharma Corp.

NervGen Pharma Corp Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of NervGen Pharma Corp. The current atr is 0.20018814.

NervGen Pharma Corp Daily Average True Range (ATR) ChartNervGen Pharma Corp Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of NervGen Pharma Corp. The current obv is -200,100.

NervGen Pharma Corp Daily On-Balance Volume (OBV) ChartNervGen Pharma Corp Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of NervGen Pharma Corp. The current mfi is 39.84.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
NervGen Pharma Corp Daily Money Flow Index (MFI) ChartNervGen Pharma Corp Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for NervGen Pharma Corp.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-07STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-08MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-11-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-13DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-20STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-27CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-28STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-30SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-01-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-01-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-02-02ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-09STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-02-12SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-01STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-15STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-21WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-22STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-25MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

NervGen Pharma Corp Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of NervGen Pharma Corp based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.822
Ma 20Greater thanMa 502.715
Ma 50Greater thanMa 1002.970
Ma 100Greater thanMa 2002.506
OpenGreater thanClose2.190
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Nervgen with someone you think should read this too:
  • Are you bullish or bearish on Nervgen? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Nervgen? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about NervGen Pharma Corp

I send you an email if I find something interesting about NervGen Pharma Corp.


Comments

How you think about this?

Leave a comment

Stay informed about NervGen Pharma Corp.

Receive notifications about NervGen Pharma Corp in your mailbox!